Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor

Monica Bartucci, Rosanna Dattilo, Daniela Martinetti, Matilde Todaro, Giuseppina Zapparelli, Antonio Di Virgilio, Mauro Biffoni, Ruggero De Maria, and Ann Zeuner

Abstract

Purpose: Chemotherapy-induced apoptosis of immature hematopoietic cells is a major cause of anemia and thrombocytopenia in cancer patients. Although hematopoietic growth factors such as erythropoietin and colony-stimulating factors cannot prevent the occurrence of drug-induced myelosuppression, stem cell factor (SCF) has been previously shown to protect immature erythroid and megakaryocytic cells in vitro from drug-induced apoptosis. However, the effect of SCF in vivo as a single myeloprotective agent has never been elucidated.

Experimental Design: The ability of SCF to prevent the occurrence of chemotherapy-induced anemia and thrombocytopenia was tested in a mouse model of cisplatin-induced myelosuppression. To highlight the importance of maintaining a continuous antiapoptotic signal in immature hematopoietic cells, we compared two treatment schedules: in the first schedule, SCF administration was interrupted during chemotherapy treatment and resumed thereafter, whereas in the second schedule, SCF was administered without interruption for 7 days, including the day of chemotherapy treatment.

Results: The administration of SCF to cisplatin-treated mice could preserve bone marrow integrity, inhibit apoptosis of erythroid and megakaryocytic precursors, prevent chemotherapy-induced anemia, and rapidly restore normal platelet production. Treatment with SCF increased the frequency of Bcl-2/Bcl-XL–positive bone marrow erythroid cells and sustained Akt activation in megakaryocytes. Myeloprotection was observed only when SCF was administered concomitantly with cisplatin and kept constantly present during the days following chemotherapy treatment.

Conclusions: SCF treatment can prevent the occurrence of chemotherapy-induced anemia and thrombocytopenia in mice, indicating a potential use of this cytokine in the supportive therapy of cancer patients.

Introduction

Chemotherapy-induced bone marrow damage results in anemia and thrombocytopenia that threaten the patients' quality of life and the overall efficacy of anticancer treatments. Hematopoietic growth factors such as erythropoietin and colony-stimulating factors are commonly used to promote hematopoietic recovery following chemotherapy, but they cannot prevent the occurrence of drug-induced myelosuppression. Stem cell factor (SCF) is produced by stromal cells of the bone marrow and binds the receptor c-kit expressed on hematopoietic stem and progenitor cells (1). It is essential for erythroid homeostasis, as mice defective for SCF or its receptor c-kit display severe macrocytic anemia and inefficient response to stress erythropoiesis (2–7). SCF administration has been shown to stimulate hematopoiesis in rodents, primates, and humans by increasing the number of bone marrow cells (8–10) and promotes recovery after cytotoxic damage (11). Besides stimulating hematopoietic cell expansion, SCF is a potent antia apoptotic factor for erythroid and megakaryocytic cells (12–15). In vitro, SCF can prevent chemotherapy-induced apoptosis of immature erythroblasts and megakaryocytes, which are exquisitely vulnerable to cytotoxic agents (14, 15). In this report, we show that SCF acts as a myeloprotective agent in vivo, being able...
to protect bone marrow cells from cisplatin-induced damage. In particular, SCF protected bone marrow erythroid (TER119<sup>+</sup>) and megakaryocytic (CD41<sup>+</sup>) precursors from chemotherapy-induced depletion and prevented the occurrence of anemia and thrombocytopenia in the peripheral blood of treated mice. We also show for the first time that the efficacy of SCF as a myeloprotective agent depends on the schedule of administration.

The observation that SCF can protect erythroid and megakaryocytic precursors in vivo provides a rationale for a future use of this cytokine in preventing drug-induced anemia and thrombocytopenia in cancer patients.

Materials and Methods

**Mice treatment**

Animal experiments were conducted according to the National Animal Experimentation Guidelines (D.L.116/92) upon approval of the experimental protocol by the Institutional Animal Experimentation Committee. Six-week-old C57/Bl6 female mice weighing approximately 20 g were purchased from Jackson Laboratories and maintained with food and water *ad libitum* for the duration of the studies. Mice were treated as follows: the "Control" group received matched PBS injections, the "Cisplatin" group received a single intraperitoneal dose of 7.5 mg/kg cisplatin (Sigma Aldrich) at day 0, the "SCF" group received 50 μg/kg recombinant murine SCF (mSCF; Peprotech) dissolved in PBS twice a day from days −1 to 7, "interrupted" mice received 7.5 mg/kg cisplatin at day 0 and 100 μg/kg mSCF at day −1 and once a day from days 1 to 7 (being SCF treatment interrupted during cisplatin administration), and "Constant" mice received cisplatin at day 0 and 50 μg/kg mSCF twice a day from days 0 to 7 (covering also the day of cisplatin administration). SCF was administered subcutaneously.

**Microscopy and flow cytometry**

Bone marrow sections were prepared as follows: At the end of the treatment, mice were sacrificed and femurs were removed, fixed in buffered paraformaldehyde 10% for 24 hours, washed, and exposed to decalcifying solution (0.05 mol/L EDTA, 5N NaOH). Samples were deparaffinized and hydrated, and staining reactions were then carried out on 6-μm-thick sections. To evaluate bone marrow cellularity, histologic sections were stained with hematoxylin/eosin. Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining was carried out with the In Situ Cell Death Detection Kit (Roche Molecular Biochemicals) according to the manufacturer’s instructions. For immunofluorescence analysis and May-Grünwald-Giemsa staining, mice were sacrificed at the end of the treatment, femurs were harvested, and marrow flushed with a 23G (0.45 × 10 mm) syringe needle to collect single-cell suspensions. For immunofluorescence analysis of mouse bone marrow cells double positive for CD41/phospho-Akt, TER119/Bcl-2, or TER119/Bcl-XL, bone marrow cells were stained with phycoerythrin (PE)-conjugated anti-CD41 (BD Pharmingen) or anti-TER119 (eBioscience) and sorted with a FACsaria flow cytometer (Becton Dickinson). Sorted cells were then stained with primary antibodies against phospho-Akt (Cell Signaling), Bcl-2 (clone C-21), or Bcl-XL (clone H5; Santa Cruz Biotechnology). Alexa-Fluor 488 secondary antibody was from Invitrogen Molecular Probes. Bone marrow sections and May-Grünwald-Giemsa–stained cells were analyzed with a Nikon Eclipse E1000 microscope equipped with PlanFluor 40× oil objectives (numerical aperture: 0.75) and PlanApo 60× oil objectives (numerical aperture: 1.4), respectively (Nikon). Images were taken with a Nikon DXM1200 RGB camera and the Nikon ACT-1 Software. Immunofluorescence images were taken with an FV1000 confocal microscope (Olympus) equipped with a 60× oil immersion objective and the Olympus Fluoview software.

To evaluate CD41<sup>+</sup> and TER119<sup>+</sup> bone marrow populations by flow cytometry, cells were harvested as described earlier and stained with PE-conjugated anti-CD41 or fluorescein isothiocyanate–conjugated anti-TER119 (eBioscience). Samples were analyzed with a FACScanto flow cytometer equipped with FACSDiva software.

**Peripheral blood analyses**

Peripheral blood was obtained from retro-orbital bleeding of mice treated as described earlier. Bleeding was carried out at day 10 for hemoglobin analysis and at days 2 → 10 for platelet analysis. Blood was dripped directly after removal into tubes containing 0.5 mol/L EDTA. The analysis of peripheral blood parameters was conducted by a contract laboratory (AppiaLab) within 2 hours from collection.

**Translational Relevance**

Chemotherapy-induced anemia and thrombocytopenia occur in a large portion of patients receiving myelosuppressive chemotherapy, leading to therapy-related complications and treatment delay/reduction/discontinuation that negatively influence patient survival. The development of effective supportive strategies for the treatment of chemotherapy-induced myelosuppression is therefore essential to improve the outcome of both conventional and targeted antineoplastic therapies. Stem cell factor (SCF) is mainly used in second-line treatment regimens for mobilization-refractory patients. Here, we show that SCF protects bone marrow from chemotherapy-induced damage and prevents the occurrence of anemia and thrombocytopenia in the peripheral blood of chemotherapy-treated mice. Importantly, only an administration schedule that maintained a constant presence of SCF during and after chemotherapy treatment could prevent bone marrow damage and consequent anemia/thrombocytopenia, thus indicating the need for an uninterrupted delivery of survival stimuli to achieve effective myeloprotection.
bleeding. For hemoglobin and platelet evaluation, mice received 2 injections of 5 mg/kg cisplatin at days 0 and 4, which was necessary to produce a constant decrease in platelet number, avoiding rebound effects that occur after a single chemotherapy treatment (16).

**Statistical analysis**

The statistical significance of results was calculated using GraphPad Prism 4 (GraphPad Software Inc.; www.graphpad.com) and analyzed by means of one-way ANOVA and Bonferroni’s multiple comparison tests. A
value of \( P < 0.05 \) is represented by a single asterisk, \( P < 0.01 \) is indicated by a double asterisk, and \( P < 0.001 \) is indicated by 3 asterisks.

Results and Discussion

To investigate whether SCF could protect bone marrow cells from chemotherapy-induced destruction in vivo, we induced myelosuppression in mice with a single dose of cisplatin and administered SCF according to 2 treatment schedules. In the cohort of mice indicated as Interrupted, SCF was administered 24 hours before and 24 hours after cisplatin injection and once daily for 6 additional days. In the cohort of mice indicated as Constant, SCF was administered 4 hours before and 4 hours after cisplatin injection and then twice a day for 6 additional days. In the Constant group, the schedule of administration ensured a constant availability of SCF throughout the treatment period, considering that SCF has an elimination half-life of approximately 8 hours (17), whereas in the Interrupted
group, this condition was intentionally not fulfilled (Fig. 1).

First, we analyzed bone marrow sections from control mice (treated with PBS or with SCF alone) and mice treated with cisplatin (in the presence or absence of SCF delivered, according to the schedules described earlier) stained with TUNEL to reveal the presence of apoptotic cells or with hematoxylin/eosin to display bone marrow structure. TUNEL-stained bone marrow sections showed a high number of apoptotic cells both in mice treated with cisplatin alone (36 ± 6 per field) and in Interrupted mice (33 ± 3 per field), whereas in Constant mice, the number of dying cells was significantly lower (9 ± 2 per field; $P < 0.001$; Fig. 2A). Upon hematoxylin/eosin staining, the bone marrow of cisplatin-treated mice showed a strong hypoplasia with myelofibrosis and clusters of dysplastic megakaryocytes (Fig. 2B, left, arrows). The bone marrow of Interrupted mice was similar to that of mice treated with cisplatin alone (Fig. 2B, left, arrows). The bone marrow of interrupted mice was similar to that of mice treated with cisplatin alone, indicating that an intermittent administration of SCF compromises the ability of this cytokine to prevent bone marrow destruction (Fig. 2B, left). These observations were confirmed by counting the absolute number of cells extracted from mouse femurs (Fig. 2B, right). In contrast, bone marrow structure and cell numbers of Constant mice resembled those of mice treated with PBS, indicating that constant administration of SCF protects bone marrow cells from chemotherapy-induced damage. The analysis of May-Grünewald-Giemsa–stained cells extracted from femurs of mice treated as described earlier showed that megakaryocytes and erythroblasts were significantly more abundant in Constant mice than in mice treated with cisplatin alone (Fig. 3A; $P < 0.001$ and $P < 0.05$, respectively).

An analysis of bone marrow cells of the granulocytic lineage on May-Grünwald-Giemsa–stained slides revealed a significant decrease of granulocytic precursors in the Cisplatin and the Interrupted samples, whereas SCF treatment restored the levels of immature granulocytes in the Constant group (data not shown). However, a massive presence of mature granulocytes in the Cisplatin and the Interrupted samples (likely represented by the long-lived bone marrow reservoir; ref. 18) rendered difficult to prove a protective effect of SCF toward the granulocytic lineage. The relative abundance of megakaryocytic and erythroid cells was confirmed by fluorescence-activated cell-sorting analysis of CD41$^+$ and TER119$^+$ cells in the bone marrow of control and treated mice, respectively (Fig. 3B and Supplementary Fig. S1).

SCF was previously shown to prevent chemotherapy-induced apoptosis of purified human erythroblasts and megakaryocytes (which were shown to represent the preferential target of drug-induced damage within the erythroid and megakaryocytic lineage, respectively) by inducing an increase in antiapoptotic factors. Specifically, SCF upregulates Bcl-2/Bcl-XL in erythroid precursors, whereas in megakaryocytes, it increases Akt activation with subsequent Bad phosphorylation (14, 15). To investigate
whether such antiapoptotic mechanisms were activated in
murine hematopoietic precursors upon SCF treatment in
vivo, we sorted cells positive for TER119 (erythroid pre-
cursors) or CD41 (megakaryocytic progenitors and mega-
karyocytes) from the bone marrow of mice treated with
vehicle, cisplatin, SCF only, or cisplatin plus SCF in the
Interrupted or Constant modality. Subsequent staining of
sorted bone marrow cells with anti-phosphorylated Akt
(for the CD41⁺ population) or with Bcl-2 or anti-Bcl-XL
(for the TER119⁺ population) showed an increased fre-
quency of Akt phosphorylation in CD41⁺ megakaryocytic
cells of Constant mice as compared with mice treated with
cisplatin alone (Fig. 4). Similarly, an increased number of
TER119⁺ bone marrow erythroid cells expressed Bcl-2 and
Bcl-XL in Constant mice as compared with mice treated
with cisplatin alone (Fig. 4). In both cases, Interrupted mice
did not differ significantly from mice treated with cisplatin
alone. These results indicate that only a continuous stim-
ulation with SCF can elicit antiapoptotic signals that act
through the mitochondrial pathway, thus preventing the
depletion of bone marrow erythroid and megakaryocytic
cells.

Then, we hoped to investigate the consequences of SCF-
induced myeloprotection on peripheral blood red cells and
platelets. To obtain a sustained decrease of hemoglobin
and platelets in the peripheral blood, mice were subjected
to 2 injections of cisplatin at days 0 and 4 of treatment,
respectively. Subsequent peripheral blood analyses
revealed that at day 10, hemoglobin levels of Constant
mice were significantly higher than those of cisplatin-trea-
ted animals (P < 0.01) and similar to those of vehicle-
treated controls, indicating that SCF efficiently prevented
the occurrence of cisplatin-induced anemia (Fig. 5A). An
assessment of platelet levels showed a progressive decrease
of platelet levels in the Cisplatin group and, to a lesser
extent, in the Interrupted group (Fig. 5B). Conversely,
platelet levels of the Constant group started to increase
after an initial reduction and, 10 days after the first che-
motherapy insult, reached the levels detected in control
animals (Fig. 5B). Altogether, these results indicate that a
constant administration of SCF can prevent the occurrence
of chemotherapy-induced anemia and thrombocytopenia
through a specific protection of immature erythroid and
megakaryocytic cells. Investigations are ongoing in our
laboratory to determine whether the protective effects
of SCF on the bone marrow may involve other immature
hematopoietic cells such as CD34⁺ hematopoietic pro-
genitors. A comprehensive analysis of pathways activat-
ed by SCF in immature hematopoietic cells conducted
by reverse-phase proteomic arrays shows activation of
multiple antiapoptotic pathways besides Bcl-2/Bcl-XL
increase and Akt phosphorylation (F. Pedini and A.
Zeuner, unpublished data), suggesting that a network
of signals activated by c-kit contributes to SCF-mediated
hematopoietic protection. The ability of SCF to activate
an extensive network of survival signals may explain the
multilineage antiapoptotic activity of this cytokine,
which would provide an advantage over more restricted

Figure 5. SCF prevents chemotherapy-induced decrease of hemoglobin
and platelets in the peripheral blood. A, hemoglobin (Hb) levels in the
peripheral blood of mice treated with SCF as described in Figure 1 and
with 5 mg/kg cisplatin at days 0 and 4. The blood was withdrawn at
day 10 by retro-orbital bledding and analyzed with an automated
analyzer. The experiment was repeated 6 times with groups of 4 mice
each. One-way ANOVA analysis with Bonferroni’s multiple comparison
tests showed a statistical significance of **, P < 0.01 between Cisplatin
and Constant group mice. B, platelet (PLT) numbers in the peripheral
blood of mice treated as in A. Mice belonging to the 5 treatment groups
were treated with 5 mg/kg cisplatin at days 0 and 4 (bolt). Blood was
obtained by retro-orbital bledding at days 2 and 10 and analyzed with an
automated analyzer. The experiment was repeated 6 times with groups
of 4 mice each.
growth factors (erythropoiesis- and granulopoiesis-stimulating agents) currently used in the supportive therapy of cancer patients. Although further in vivo experiments with non-human primates would be useful to confirm the myeloprotective activity of SCF, this cytokine may find a future use to prevent drug-induced anemia and thrombocytopenia in cancer patients with tumors that do not rely on c-kit signaling for growth and survival.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Acknowledgments

We thank Dr. Paola Cosentino (Appialab center for veterinary analysis, Rome) for discussion and support, Giuseppe Loreto for graphics, and Stefano Guida for technical assistance.

Grant Support

This work was supported by the Italian Association for Cancer Research (AIRC; Investigator grant 5717 to A. Zeuner and fellowship to G. Zapparelli). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 12, 2011; revised July 19, 2011; accepted August 9, 2011; published OnlineFirst August 25, 2011.